IMPACT
- IHF-supported deployment of Truenat in two districts in Uttar Pradesh demonstrated significant improvement in testing presumptive TB patients – with 92% of the samples tested reporting results on the same day. Treatment initiation time improved by 45% as compared to the baseline, and 96% patients initiated their treatment within seven days of test results. Truenat was also validated for effectiveness as a TB/COVID-19 diagnostic test at community health centres in Uttar Pradesh with support from India Health Fund.
- IHF with The Foundation for Innovative New Diagnostics (FIND) and Municipal Corporation of Greater Mumbai (MCGM) successfully implemented India’s largest bi-directional testing for TB and COVID-19 using Truenat in five high volume COVID-19 tertiary hospitals. The initiative screened more than 17,000 antigen negative symptomatic patients, and 13,500 COVID-19 OPD walk-ins went through the TB questionnaire followed by diagnosis using Truenat. Of these, 2.7% (379) were identified as TB presumptive and 78% (297) were tested for TB (until September 2021).
- Through a global pricing agreement signed in March 2023, Truenat has been approved for worldwide scale-up by the Global Fund, StopTB Partnership and USAID. The agreement will enable countries to procure the WHO endorsed-Truenat at internationally negotiated prices, making the technology more accessible and affordable across the world.
“The strong engagement with the user community as well as with public health experts that the India Health Fund enables, greatly smoothens the lab-to-market journey and facilitates deployment at scale. Such support from IHF has been invaluable for Molbio during the scaleup of the Truenat platform.”
Chandrasekhar Nair, Co-Founder & Chief Technology Officer, Molbio Diagnostics
